Peter Rose

8PUBLICATIONS

79CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMedical molecular engineering of nucleic acids and proteins

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (8)

Sort by Publication Date:

|May 29, 2026

Improving survival in recurrent ovarian cancer, miles to go before we sleep.

|Jan 23, 2026

Gram-positive targeting antibiotics are associated with progression and death in women with platinum-sensitive recurrent high grade epithelial ovarian cancer.

Laura M Chambers, Julia Chalif, Meng Yao

|Dec 11, 2025

Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.

Robert L Hollis, Austin Miller, Heather A Lankes

|Apr 07, 2025

Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial.

Jung-Min Lee, Austin Miller, Peter G Rose

|Oct 03, 2024

Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.

Jung-Min Lee, Mark F Brady, Austin Miller

|Aug 18, 2023

Fam-Trastuzumab Deruxtecan in HER2/Neu-Expressing Serous Endometrial Cancer.

Peter G Rose, Johanna A Kelley, Myra Feldman

Pageof 2

Frequent Collaborators

Austin Miller

Laura M Chambers

Ofer Reizes

Jung-Min Lee

Kathleen N Moore

Roberto Vargas

Chad M Michener

John K Chan

Angeles Alvarez Secord

1 joint publications

Mark F Brady

Frequent Collaborators

Austin Miller

Laura M Chambers

Ofer Reizes

Jung-Min Lee